<code id='EA030641F3'></code><style id='EA030641F3'></style>
    • <acronym id='EA030641F3'></acronym>
      <center id='EA030641F3'><center id='EA030641F3'><tfoot id='EA030641F3'></tfoot></center><abbr id='EA030641F3'><dir id='EA030641F3'><tfoot id='EA030641F3'></tfoot><noframes id='EA030641F3'>

    • <optgroup id='EA030641F3'><strike id='EA030641F3'><sup id='EA030641F3'></sup></strike><code id='EA030641F3'></code></optgroup>
        1. <b id='EA030641F3'><label id='EA030641F3'><select id='EA030641F3'><dt id='EA030641F3'><span id='EA030641F3'></span></dt></select></label></b><u id='EA030641F3'></u>
          <i id='EA030641F3'><strike id='EA030641F3'><tt id='EA030641F3'><pre id='EA030641F3'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:entertainment    - browse:1381
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          entertainment